Haemonetics Corporation (HAE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 8, 2026. The Healthcare name (Medical Devices) last closed at $119.47. The rating moved from Neutral to Overbought on October 8, 2026.

• Public ratingOverbought (as of October 8, 2026)
• Last close$119.47
• Last changeMoved from Neutral to Overbought on October 8, 2026
• SectorHealthcare
• IndustryMedical Devices

See all overbought Healthcare stocks →

AI analysis

Haemonetics benefits from a recurring-consumable business model and a leading installed base in blood-management solutions, supporting steady cash flow and margin recovery potential. Near-term upside is supported by positive market sentiment and earnings-season momentum, while longer-term growth depends on procedure volumes, international expansion, and successful execution of efficiency initiatives. Key vulnerabilities include reimbursement/headroom pressure in hospital budgets, competition, and supply‑chain or execution risks that could temper topline or margin progress.

Key factors

• High recurring revenue mix from disposables and an installed base that supports steady aftermarket sales
• Established market position in blood-management systems and devices with differentiated product portfolio
• Earnings-season momentum and recent positive premarket social sentiment supporting near-term price stability
• Opportunity for margin expansion via operational efficiency initiatives and pricing on consumables
• Defensive cash generation and potential for capital allocation (buybacks/M&A) to enhance shareholder returns
• Elective procedure recovery and international expansion provide organic growth catalysts

Risks

• Reimbursement and hospital budget pressure (Medicare policies and hospital capex constraints) that could reduce equipment purchases and consumable utilization
• Competitive pressure from other medtech firms leading to pricing concessions or share loss
• Execution risk on new product rollouts, integrations, and cost-savings initiatives
• Supply-chain disruptions or input-cost inflation that compress gross margins
• Exposure to slower-than-expected elective procedure volumes if macro or regional healthcare demand softens
• Limited near-term visibility into revenue cadence without recent detailed EDGAR filing comparison

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.